Eli Lilly
and Company LLY and Boehringer Ingelheim International GmbH announced
today they will adjust the scope of their diabetes alliance with respect to
LY2605541*, Lilly's novel basal insulin analog, with Lilly reassuming sole
worldwide development and commercialization rights to LY2605541.
Lilly and Boehringer Ingelheim formed their diabetes alliance in January 2011,
centering on four pipeline compounds representing several of the largest and
most promising product classes. It is one of the largest alliances among two
pharmaceuticals companies ever in a single therapeutic area and aims to
provide a broad portfolio of treatment options for patients with diabetes and
their healthcare professionals.
While Lilly and Boehringer Ingelheim will continue to jointly develop and
commercialize the other assets in the alliance, Boehringer Ingelheim elected
to terminate the collaboration with Lilly with respect to LY2605541 given
independent strategic portfolio considerations.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in